Anne Prener
Director/Board Member chez GALECTO, INC.
Fortune : - $ au 31/03/2024
Profil
Anne Prener is currently serving as the President, Chief Executive Officer & Director at Imbria Pharmaceuticals, Inc. She is also an Independent Director at Galecto, Inc. and a Director at Cellinta Ltd.
Additionally, she holds the position of Venture Partner at SV Health Investors LLP.
In her former roles, Dr. Prener served as the Chief Executive Officer at Syncona Ltd.
She was also the Chief Executive Officer & Director at Freeline Therapeutics Ltd.
from 2017 to 2019, and the Chief Executive Officer at Gyroscope Therapeutics Ltd.
from 2016 to 2019.
Furthermore, she served as an Independent Director at Rubius Therapeutics, Inc. from 2019 to 2022 and as a Director at Renovacor Holdings, Inc. and Kaleido Biosciences, Inc. Dr. Prener's earlier experience includes positions at Novo Nordisk A, where she served as the SVP-Hemophilia Research & Development Portfolio from 2012 to 2013 and as the Senior Vice President from 2011 to 2013.
She also held the role of Vice President-Clinical Research Hematology at Baxalta, Inc. from 2014 to 2016.
Additionally, she served as a Council/Board member at Novo Nordisk (Private Equity) from 2010 to 2014.
Dr. Prener obtained her doctorate degree from the University of Copenhagen.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
GALECTO, INC.
-.--% | 14/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Anne Prener
| Sociétés | Poste | Début |
|---|---|---|
| GALECTO, INC. | Director/Board Member | 08/01/2021 |
Cellinta Ltd.
 Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Director/Board Member | 27/03/2020 |
Imbria Pharmaceuticals, Inc.
 Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Chief Executive Officer | 01/07/2020 |
SV Health Investors LLP
 SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Private Equity Investor | 01/09/2020 |
Anciens postes connus de Anne Prener
| Sociétés | Poste | Fin |
|---|---|---|
| RUBIUS THERAPEUTICS | Director/Board Member | 12/07/2022 |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Chief Executive Officer | 01/07/2019 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Chief Executive Officer | 01/03/2019 |
| BAXALTA INC | Corporate Officer/Principal | 01/07/2016 |
Novo Nordisk (Private Equity)
 Novo Nordisk (Private Equity) Investment ManagersFinance Novo Nordisk A/S (CO: NOVO.B; NYSE: NVO), a Danish healthcare company which manufactures and markets pharmaceutical products and services worldwide, invests through their corporate venture fund NNBF-Novo Nordisk Biotech Fund (NNBF). Based in Bagsværd near Copenhagen, NNBF is a business unit within Novo Nordisk A/S, responsible for the company's venture capital activities. Investments are made on the books of Novo Nordisk A/S out of internal financial resources. NNBF is managed as an evergreen fund. | Director/Board Member | 01/10/2014 |
Formation de Anne Prener
| University of Copenhagen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| NOVO NORDISK A/S | Health Technology |
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| GALECTO, INC. | Health Technology |
| Entreprise privées | 10 |
|---|---|
SV Health Investors LLP
SV Health Investors LLP Investment ManagersFinance SV Health Investors LLP (SV Health Investors) is an Independent Venture Capital firm founded in 1994 by Peter McPartland. The firm is headquartered in London. | Finance |
Syncona Ltd.
 Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Syncona Ltd. is a closed-end investment fund. It engages in delivering returns from investments in long and alternative investment funds across multiple asset classes and targets. The company was founded on August 14, 2012, and is headquartered in St. Peter Port, the United Kingdom. | Miscellaneous |
Baxalta, Inc.
 Baxalta, Inc. BiotechnologyHealth Technology Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL. | Health Technology |
Novo Nordisk (Private Equity)
Novo Nordisk (Private Equity) Investment ManagersFinance Novo Nordisk A/S (CO: NOVO.B; NYSE: NVO), a Danish healthcare company which manufactures and markets pharmaceutical products and services worldwide, invests through their corporate venture fund NNBF-Novo Nordisk Biotech Fund (NNBF). Based in Bagsværd near Copenhagen, NNBF is a business unit within Novo Nordisk A/S, responsible for the company's venture capital activities. Investments are made on the books of Novo Nordisk A/S out of internal financial resources. NNBF is managed as an evergreen fund. | Finance |
Rubius Therapeutics, Inc.
 Rubius Therapeutics, Inc. BiotechnologyHealth Technology Rubius Therapeutics, Inc. engages in the development of red-cell therapeutic medicines. It provides medicine for cancer, autoimmune diseases, hemophilia, infectious and metabolic diseases. The company was founded on April 26, 2013 and is headquartered in Foxboro, MA. | Health Technology |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Freeline Therapeutics Ltd. operates as a biopharmaceutical company, which develops gene therapies for bleeding and other debilitating disorders. The company was founded by Chris Hollowood in 2015 and is headquartered in London, the United Kingdom. | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Imbria Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company developing novel therapies that restore cellular energy deficits. It focuses on restoring or improving the cell?s ability to produce energy where energy imbalances are at the root of disease, including cardiovascular diseases and inborn errors of metabolism. The company was founded by Andrew Levin and David-Alexandre C. Gros in 2018 and is headquartered in Boston, MA. | Health Technology |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Renovacor Holdings, Inc.
 Renovacor Holdings, Inc. BiotechnologyHealth Technology Renovacor, Inc. operates as a preclinical stage biopharmaceutical company focused on developing transformative gene therapy based treatments for cardiovascular disease. The company is headquartered in Philadelphia, PA. | Health Technology |
Cellinta Ltd.
Cellinta Ltd. Investment ManagersFinance Cellinta Ltd. operates as a biotechnology firm. The company was founded on August 16, 2019 and is headquartered in Reading, the United Kingdom. | Finance |
